Grail (GRAL) Stock Plummets 50% After NHS Cancer Trial Fails Primary Endpoint

Grail's stock suffered a catastrophic 50% collapse in after-hours trading following the disappointing results of its NHS-Galleri cancer trial. The much-anticipated blood test failed to demonstrate statistically significant reduction in late-stage cancers across the full trial population, dealing a severe blow to investor confidence.

While the trial's primary endpoint was missed, a glimmer of hope emerged from subgroup analysis. The Galleri test showed promising 20%+ reduction in Stage IV diagnoses for 12 deadly cancer types in years two and three of the study. This silver lining suggests potential niche applications despite the broader failure.

Financial metrics offered little consolation. Grail reported a Q4 loss of $2.44 per share, slightly better than expected, with revenues hitting the $43.6 million target. The company has proceeded with its FDA premarket approval application, incorporating first-year NHS trial data in its submission.

The market reaction was swift and brutal. Shares cratered 48% to $52.25 after hours, continuing their descent to $53.33 in premarket trading. This dramatic reversal erased the stock's impressive 200% gains from the previous six months, highlighting the binary nature of biotech investing.